INCY
Neutral signalScored 2026-10-25 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Incyte Corporation
- Nom
- Incyte Corporation
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $23.4B
- Employés
- 2,844
- PDG
- William J. Meury
- Site web
- https://www.incyte.com
- Marché
- AVBPCGEMEXELGMABLEGNLGND
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$9,119,670
Avg sell (VWAP, 90d window) $121.09 vs last close $113.31 (-6.4%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$8,821,890 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- —
- Liquidity
- Liquid $203,208,494/day · 20d vol
- Last synced
-
2026-10-26 21:10:35
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | CAGNONI PABLO J | Sell · S | 2,642 | $112.71 | $297,780 | Form 4 |
| 2026-09-15 | CAGNONI PABLO J | Sell · S · 10b5-1 | 13,985 | $120.49 | $1,685,053 | Form 4 |
| 2026-08-19 | CAGNONI PABLO J | Sell · S · 10b5-1 | 10,801 | $125.56 | $1,356,174 | Form 4 |
| 2026-08-12 | CAGNONI PABLO J | Sell · S · 10b5-1 | 10,803 | $120.04 | $1,296,792 | Form 4 |
| 2026-08-05 | CAGNONI PABLO J | Sell · S · 10b5-1 | 10,640 | $122.69 | $1,305,422 | Form 4 |
| 2026-08-05 | Mayes Patrick A | Sell · S · 10b5-1 | 2,207 | $123.99 | $273,646 | Form 4 |
| 2026-08-03 | Mayes Patrick A | Sell · S · 10b5-1 | 6,055 | $120.43 | $729,204 | Form 4 |
| 2026-07-31 | CAGNONI PABLO J | Sell · S · 10b5-1 | 15,888 | $119.70 | $1,901,794 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Sell · S · 10b5-1 | 2,293 | $119.41 | $273,807 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-03-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2023-01-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2020-12-22 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2020-09-16 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-25 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
INCY presents a compelling financial profile — pristine balance sheet, strong cash generation, and expanding margins — but the event-driven signal is weak, with a catalyst score of only 25, no insider buying, and no…
The first sentence of the analysis written for INCY on 2026-10-25 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 3.32 · operating margin 26%
Suggested stop 106.18, nearest stored support minus 0.5 ATR(6.3% under the last close). Reward/risk to the next stored resistance is 0.88. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-24 Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer [url="]Genmab A/S[/url] (Nasdaq: GMAB) and [url="]Incyte[/url] (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab''s
- 2026-10-24 Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)---- $INCY--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer.
- 2026-10-24 Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte''s investigational, potent and se
- 2026-10-24 Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer Media ReleaseCOPENHAGEN, Denmark and WILMINGTON, Del. ; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab''s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte''s investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring a KRAS G12D mutation, an area with substantial unmet medical need.
- 2026-10-23 Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint? INCY''s Q3''26 results hinge on Jakafi''s strong sales, Opzelura''s growth and rising royalties, while higher operating expenses may pressure earnings.
- 2026-10-22 Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option Prelude Therapeutics NASDAQ: PRLD outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer and a mutant calreticulin, or mCALR, program for myeloproliferative neoplasms.
- 2026-10-22 Analysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out for Incyte (INCY) doesn''t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-10-20 Incyte (NASDAQ:INCY) Insider Pablo Cagnoni Sells 2,642 Shares of Company Stock Incyte Corporation (NASDAQ: INCY - Get Free Report) insider Pablo Cagnoni sold 2,642 shares of the firm''s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $112.71, for a total value of $297,779.82. Following the completion of the sale, the insider owned 183,200 shares of the company''s stock,
- 2026-10-18 Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology (ESMO) Congress 2
- 2026-10-18 Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO2026--Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 92.8% | 92.6% | 93.1% | 93.9% | 94.9% | |
| Ebit Margin | 32.4% | 7.5% | 22.6% | 15.7% | 19.2% | |
| Ebitda Margin | 34.2% | 9.6% | 24.9% | 17.7% | 21.1% | |
| Operating Profit Margin | 26.1% | 2.4% | 17.7% | 17.4% | 19.6% | |
| Pretax Profit Margin | 32.4% | 7.5% | 22.6% | 15.6% | 19.1% | |
| Continuous Operations Profit Margin | 25.0% | 0.8% | 16.2% | 10.0% | 31.8% | |
| Net Profit Margin | 25.0% | 0.8% | 16.2% | 10.0% | 31.8% | |
| Bottom Line Profit Margin | 25.0% | 0.8% | 16.2% | 10.0% | 31.8% | |
| Current Ratio | 3.316 | 1.973 | 3.745 | 3.537 | 3.651 | |
| Quick Ratio | 3.249 | 1.937 | 3.694 | 3.501 | 3.618 | |
| Solvency Ratio | 0.765 | 0.061 | 0.427 | 0.278 | 0.865 | |
| Cash Ratio | 2.045 | 1.028 | 2.591 | 2.551 | 2.408 | |
| Price To Earnings Ratio | 14.988 | 431.687 | 23.517 | 52.497 | 17.070 | |
| Price To Earnings Growth Ratio | 0.004 | -4.592 | 0.316 | -0.815 | -0.041 | |
| Forward Price To Earnings Growth Ratio | 0.004 | -4.592 | 0.316 | -0.815 | -0.041 | |
| Price To Earnings Diluted Ratio | 15.409 | 460.467 | 23.694 | 52.842 | 17.190 | |
| Price To Earnings Diluted Growth Ratio | 0.004 | -4.881 | 0.319 | -0.820 | -0.042 | |
| Price To Book Ratio | 3.731 | 4.149 | 2.706 | 4.080 | 4.292 | |
| Price To Sales Ratio | 3.750 | 3.373 | 3.799 | 5.253 | 5.418 | |
| Price To Free Cash Flow Ratio | 14.233 | 57.433 | 30.262 | 19.988 | 28.461 | |
| Price To Operating Cash Flow Ratio | 13.640 | 42.659 | 28.282 | 18.384 | 21.587 | |
| Debt To Assets Ratio | 0.010 | 0.008 | 0.006 | 0.007 | 0.009 | |
| Debt To Equity Ratio | 0.013 | 0.013 | 0.007 | 0.009 | 0.012 | |
| Debt To Capital Ratio | 0.013 | 0.012 | 0.007 | 0.009 | 0.012 | |
| Long Term Debt To Capital Ratio | 0.003 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.346 | 1.579 | 1.307 | 1.337 | 1.309 | |
| Working Capital Turnover Ratio | 2.014 | 1.696 | 1.166 | 1.306 | 1.496 | |
| Operating Cash Flow Ratio | 0.933 | 0.204 | 0.400 | 0.838 | 0.877 | |
| Operating Cash Flow Sales Ratio | 0.275 | 0.079 | 0.134 | 0.286 | 0.251 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.958 | 0.743 | 0.935 | 0.920 | 0.758 | |
| Debt Service Coverage Ratio | 109.356 | 54.449 | 267.664 | 154.231 | 528.476 | |
| Interest Coverage Ratio | 553.044 | 44.427 | 256.902 | 221.915 | 307.011 | |
| Short Term Operating Cash Flow Coverage Ratio | 138.402 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 20.359 | 7.701 | 12.968 | 23.396 | 16.722 | |
| Capital Expenditure Coverage Ratio | 24.012 | 3.887 | 15.283 | 12.462 | 4.141 | |
| Dividend Paid And Capex Coverage Ratio | 24.012 | 3.887 | 15.283 | 12.462 | 4.141 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 9.233 | 31.019 | 11.819 | 24.884 | 22.480 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 92.8% | ▲0.1% | ▼-0.7% |
| Ebit Margin | 32.4% | ▲24.9% | ▲12.9% |
| Ebitda Margin | 34.2% | ▲24.6% | ▲12.7% |
| Operating Profit Margin | 26.1% | ▲23.7% | ▲9.5% |
| Pretax Profit Margin | 32.4% | ▲24.9% | ▲13.0% |
| Continuous Operations Profit Margin | 25.0% | ▲24.3% | ▲8.3% |
| Net Profit Margin | 25.0% | ▲24.3% | ▲8.3% |
| Bottom Line Profit Margin | 25.0% | ▲24.3% | ▲8.3% |
| Current Ratio | 3.316 | ▲1.343 | ▲0.071 |
| Quick Ratio | 3.249 | ▲1.312 | ▲0.049 |
| Solvency Ratio | 0.765 | ▲0.704 | ▲0.286 |
| Cash Ratio | 2.045 | ▲1.016 | ▼-0.080 |
| Price To Earnings Ratio | 14.988 | ▼-416.700 | ▼-92.964 |
| Price To Earnings Growth Ratio | 0.004 | ▲4.596 | ▲1.030 |
| Forward Price To Earnings Growth Ratio | 0.004 | ▲4.596 | ▲1.030 |
| Price To Earnings Diluted Ratio | 15.409 | ▼-445.058 | ▼-98.512 |
| Price To Earnings Diluted Growth Ratio | 0.004 | ▲4.885 | ▲1.088 |
| Price To Book Ratio | 3.731 | ▼-0.418 | ▼-0.060 |
| Price To Sales Ratio | 3.750 | ▲0.377 | ▼-0.569 |
| Price To Free Cash Flow Ratio | 14.233 | ▼-43.200 | ▼-15.842 |
| Price To Operating Cash Flow Ratio | 13.640 | ▼-29.019 | ▼-11.270 |
| Debt To Assets Ratio | 0.010 | ▲0.002 | ▲0.002 |
| Debt To Equity Ratio | 0.013 | ▲0.001 | ▲0.003 |
| Debt To Capital Ratio | 0.013 | ▲0.001 | ▲0.002 |
| Long Term Debt To Capital Ratio | 0.003 | ▲0.003 | ▲0.002 |
| Financial Leverage Ratio | 1.347 | ▼-0.233 | ▼-0.029 |
| Working Capital Turnover Ratio | 2.014 | ▲0.318 | ▲0.478 |
| Operating Cash Flow Ratio | 0.933 | ▲0.729 | ▲0.282 |
| Operating Cash Flow Sales Ratio | 0.275 | ▲0.196 | ▲0.070 |
| Free Cash Flow Operating Cash Flow Ratio | 0.958 | ▲0.216 | ▲0.096 |
| Debt Service Coverage Ratio | 109.356 | ▲54.907 | ▼-113.480 |
| Interest Coverage Ratio | 553.044 | ▲508.616 | ▲276.384 |
| Short Term Operating Cash Flow Coverage Ratio | 138.402 | ▲138.402 | ▲110.722 |
| Operating Cash Flow Coverage Ratio | 20.359 | ▲12.658 | ▲4.130 |
| Capital Expenditure Coverage Ratio | 24.012 | ▲20.124 | ▲12.055 |
| Dividend Paid And Capex Coverage Ratio | 24.012 | ▲20.124 | ▲12.055 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 9.233 | ▼-21.786 | ▼-10.654 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $19.28B | $14.31B | $14.04B | $17.83B | $16.18B | |
| Enterprise value | $16.25B | $12.66B | $10.87B | $14.92B | $14.17B | |
| EV / Sales | 3.16x | 2.98x | 2.94x | 4.40x | 4.74x | |
| EV / Op. cash flow | 11.50x | 37.76x | 21.89x | 15.38x | 18.90x | |
| EV / Free cash flow | 12.00x | 50.83x | 23.42x | 16.73x | 24.92x | |
| EV / EBITDA | 9.23x | 31.02x | 11.82x | 24.88x | 22.48x | |
| Net debt / EBITDA | -1.72x | -4.03x | -3.45x | -4.85x | -3.19x | |
| Current ratio | 3.32x | 1.97x | 3.75x | 3.54x | 3.65x | |
| Income quality | 1.10x | 10.28x | 0.83x | 2.85x | 0.79x | |
| Graham number | $63 | $8 | $37 | $26 | $41 | |
| Graham net-net | $13 | $4 | $12 | $10 | $8 | |
| Tax burden | 77.3% | 10.3% | 71.6% | 64.4% | 166.3% | |
| Interest burden | 99.9% | 99.3% | 99.7% | 99.5% | 99.7% | |
| Working capital | $3.51B | $1.60B | $3.41B | $2.94B | $2.26B | |
| Invested capital | $4.52B | $2.66B | $4.46B | $3.99B | $3.32B | |
| Return on assets | 18.5% | 0.6% | 8.8% | 5.8% | 19.2% | |
| Operating ROA | 21.7% | 1.7% | 10.4% | 11.0% | 13.8% | |
| Return on tangible assets | 19.2% | 0.6% | 9.2% | 6.1% | 20.5% | |
| Return on equity | 24.9% | 0.9% | 11.5% | 7.8% | 25.2% | |
| Return on invested capital | 20.6% | 0.3% | 8.5% | 8.1% | 14.3% | |
| Return on capital employed | 24.7% | 2.7% | 11.8% | 12.6% | 14.4% | |
| Earnings yield | 6.7% | 0.2% | 4.3% | 1.9% | 5.9% | |
| Free cash flow yield | 7.0% | 1.7% | 3.3% | 5.0% | 3.5% | |
| Capex / Op. cash flow | 4.2% | 25.7% | 6.5% | 8.0% | 24.2% | |
| Capex / Depreciation | 63.1% | 96.7% | 39.3% | 114.7% | 312.9% | |
| Capex / Sales | 1.1% | 2.0% | 0.9% | 2.3% | 6.1% | |
| SG&A / Sales | 26.8% | 28.8% | 31.3% | 29.5% | 24.8% | |
| R&D / Sales | 39.9% | 61.5% | 44.0% | 46.7% | 48.8% | |
| Stock comp / Sales | 4.8% | 6.3% | 5.8% | 5.6% | 6.1% | |
| Intangibles / Total assets | 3.6% | 4.9% | 4.1% | 4.9% | 6.2% | |
| Days sales outstanding | 73d | 73d | 73d | 69d | 75d | |
| Days payables outstanding | 206d | 231d | 157d | 489d | 416d | |
| Operating cycle | 172d | 142d | 164d | 143d | 143d | |
| Cash conversion cycle | -34d | -89d | 7d | -346d | -273d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years